Oculis

Central African Republic
Bayanga, Sangha-Mbaéré, Central African Republic

Company profile

Oculis company profile

The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops.

Business identity

Contact email
[email protected]
Phone number
+354 546-4440
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Founded
2003-01-01

Headquarters

Country code
CF
Continent
Africa

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
16
Total equity funding
$493.5M
Last funding
Post IPO Equity / $110M / 2025-10-30
Last equity funding
Post IPO Equity / $110M
Investors
15
Lead investors
10
Founders
2
Articles
197
Exited on
2023-03-03

Founders and investors

Founders

Einar StefanssonThorsteinn Loftsson

Lead investors

Bay City CapitalBlackRockBrunnur VenturesBVCFHyfinity InvestmentsNovartis Venture FundPivotal bioVenture PartnersSilfurbergTechnology Development FundTekla Capital Management

Investors

BlackRockEarlybird Venture CapitalNan Fung Life SciencesPivotal bioVenture PartnersVI Partners